Methods: A case-control study involving 46 subjects with lung cancer as well as 62 subjects with no lung cancer at pulmonology clinic, Persahabatan Hospital, Jakarta between July 2016 and October 2017 was done. The data regarding ages, jobs, active smokers, passive smokers, history of cancer in their families, history of chronic lung diseases, and EGFR mutation in subjects with lung cancer were obtained. Descriptive statistics, chi square hypothesis test, and logistic regression were used for analysis.
the subjects in the case group showed the histopathology of adenocarcinoma, and 67.4% of them showed EGFR mutations. Subjects in the control group were mostly diagnosed with pulmonary tuberculosis(43.5%). The result of bivariate analysis showed that there is a significant association between passive smoker(P = 0.038, OR = 2,613; 95% CI:1038-6575) and age (P = 0,002; OR = 5378; 95% CI: 1698-17,029) with lung cancer in women. From multivariate analysis, it was found that there was a significant association between passive smoker(P = 0.047, aOR = 2,639, 95% CI: 1012-6878) and age(P = 0,005; aOR = 5,417; 95% CI: 1,685-17,412) with the occurrence of lung cancer in women.
Conclusion:
We concluded that adenocarcinoma is the most common types of lung cancer in women and age above 40 years is the factor most associated with the occurrence of lung cancer in women at Persahabatan Hospital. assay to confirm the expression pattern of BRAF V600E protein in lung ADCs harbouring the BRAF V600E mutation.
Results: In total, we identified 33 lung ADC patients with BRAF V600E mutation. The median age was 67.5 years, 51.5% were male, 39.4% were current/former smokers, and 78.8% had Stage IV NSCLC.
IHC demonstrated that the majority of lung ADC harbouring BRAF V600E exhibited a moderate to strong cytoplasmic expression. In only 3 of 30 (10%), IHC staining failed to identify BRAF V600E. Most of BRAF V600E positive IHC cases had micropapillary histological pattern with diffuse cytoplasmic distribution. For clinical outcomes, four patients did not relapse after treatment and still survive for 12.8 (Stage IB), 21(Stage II), 27.5(Stage IIIA) and 34.1(Stage IIIA) months after diagnosis. At time of review, 29 had metastatic status (M1 disease) and 25 patients were deceased. Median (95%CI) OS from date of the metastatic disease was 10.8 (0.7, 20.9) months. Twenty-six patients received ≥1 line of systemic therapy for metastatic disease. Pemetrexed-platinum doublet chemotherapy was the most common first-line (1L) regimen (20 patients, 53.8% of 1L recipients). Patients received pemetrexed-based chemotherapy demonstrated a significant longer OS [23.6 (n = 18) vs 2.9 (n = 11) months, Log-rank test = 0.0014].
These findings indicate that BRAF V600E antibody had high sensitivity (90%) to detect BRAF V600E mutation. Conventional chemotherapy, particularly pemetrexed containing regimens may be still considered as an important care for the metastatic BRAF V600E-lung ADC patients who were unable to receive the combination of dabrafenib and trametinib treatment. neoplasms. These tumours have a complex aetiology and biology causing difficulties in classifying them histologically. Neuroendocrine tumours are classified as typical carcinoids, atypical carcinoids, small cell or large cell carcinomas. The detailed clinical features are still unknown but several studies suggest that they are usually associated with systemic symptoms due to secretion of biogenic amines from metastatic lesion whereas others are primary tumours of the thymus. Data as to the trend of management and prognosis are scarce due to limited number of studies.
Methods: CASE PRESENTATION: We report a case of a primary neuroendocrine tumor of the thymus in a 41 year-old male who had on and off chest pain with easy fatigability, diagnosed with anterior mediastinal mass. Chest CT-scan showed a left anterior mediastinal mass to consider thymoma that was resected surgically. Immunohistochemical studies showed neoplastic cells positive to Pancytokeratin, Neuron Specific Eolase and Chromografin test.
Results: Chest CT-scan showed a left anterior mediastinal mass to consider thymoma that was resected surgically. Immunohistochemical studies showed neoplastic cells positive to Pancytokeratin, Neuron Specific Eolase and Chromografin test.
This neoplasm is reported to have symptoms that may vary due to various endocrine abnormalities. Surgical resection offers the best chance for a definitive diagnosis and remains the treatment of choice. Aggressive chemotherapy maybe helpful for the improvement of the quality of life, delaying local recurrence, and increasing survival.
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